AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Discover effective ways to increase your savings rate, helping you reach your financial goals faster.
22,326 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Turning Point Brands stock has fallen today even after a strong quarterly report. This article explains what happened...
With American Express set to report on July 24, analysts say a durable franchise, disciplined capital returns, and a ...
Opal Fuels closed 2025 with growing RNG-based fueling capacity and a clearer path to profitability. This article brea...
Astera Labs stands at an inflection point: rapid AI demand could lift the stock, but margin pressures and a premium v...
This week brought a notable rise for Corcept Therapeutics as investors reacted to a major catalyst. Learn what drove ...
This article dives into EverCommerce (evcm) 2026 earnings, unpacking Q1 results, growth drivers, and the implications...
LifeStance Health Group stunned the market with a beat-and-raise quarter, sending its stock up roughly 20%. This deep...
CubeSmart sits in a crowded self-storage field. This guide breaks down the key indicators I watch to assess whether C...
As traditional bonds struggle to keep pace with inflation, boomers are flocking to high-yield ETFs paying that 10% yi...
Investors face a pivotal call on NEOS QQQI as the market navigates inflation signals, tech strength, and geopolitical...
Investors are increasingly turning to a dividend-focused portfolio to generate six-figure annual income with multi-mi...